Nanjing Leads Biolabs Co., Ltd. (HKG:9887)
Hong Kong
· Delayed Price · Currency is HKD
65.70
-2.90 (-4.23%)
Aug 14, 2025, 3:45 PM HKT
Nanjing Leads Biolabs Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 |
| Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Revenue | - | - | 8.87 |
| Cost of Revenue | - | - | 3.19 |
| Gross Profit | - | - | 5.68 |
| Selling, General & Admin | 92.69 | 87.69 | 38.05 |
| Research & Development | 200.16 | 185.68 | 230.86 |
| Operating Expenses | 292.85 | 273.38 | 268.91 |
| Operating Income | -292.85 | -273.38 | -263.23 |
| Interest Expense | -6.92 | -5.76 | -1.4 |
| Interest & Investment Income | 9.57 | 8.29 | 6.55 |
| Currency Exchange Gain (Loss) | 1.35 | 2.04 | 2.77 |
| Other Non Operating Income (Expenses) | 7.92 | 7.96 | 3.96 |
| EBT Excluding Unusual Items | -280.93 | -260.85 | -251.35 |
| Gain (Loss) on Sale of Investments | 1.65 | 1.72 | 6.44 |
| Other Unusual Items | -10.74 | -42.08 | -117.33 |
| Pretax Income | -290.01 | -301.22 | -362.25 |
| Net Income | -290.01 | -301.22 | -362.25 |
| Net Income to Common | -290.01 | -301.22 | -362.25 |
| Shares Outstanding (Basic) | 153 | 150 | 145 |
| Shares Outstanding (Diluted) | 153 | 150 | 145 |
| Shares Change (YoY) | - | 3.56% | - |
| EPS (Basic) | -1.90 | -2.01 | -2.50 |
| EPS (Diluted) | -1.90 | -2.01 | -2.50 |
| Free Cash Flow | -110.37 | -121.79 | -204.41 |
| Free Cash Flow Per Share | -0.72 | -0.81 | -1.41 |
| Gross Margin | - | - | 64.07% |
| Operating Margin | - | - | -2969.26% |
| Profit Margin | - | - | -4086.28% |
| Free Cash Flow Margin | - | - | -2305.84% |
| EBITDA | -273.7 | -253.13 | -243.49 |
| D&A For EBITDA | 19.16 | 20.24 | 19.74 |
| EBIT | -292.85 | -273.38 | -263.23 |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.